Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis

Journal of Clinical Pathology

Volumn 67, Issue 8, 2014, Pages 707-711

  Hubers, A Jasmijn ^a   Brinkman, Paul ^b   Boksem, Remco J ^b   Rhodius, Robert J ^b   Witte, Birgit I ^a   Zwinderman, Aeilko H ^c   Heideman, Daniëlle A M ^a   Duin, Sylvia ^a   Koning, Remco ^a   Steenbergen, Renske D M ^a   Snijders, Peter J F ^a   Smit, Egbert F ^a   Sterk, Peter J ^b   Thunnissen, Erik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTICS; GENETICS; LUNG CANCER; MOLECULAR ONCOLOGY; SPUTUM;

AGED; BREATH TESTS; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SENSITIVITY AND SPECIFICITY; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84905107858     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202414     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Patz EF, Rossi S, Harpole DH, et al. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 2000;117:1568-71. (Pubitemid 30413345)
4. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
5. Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980-91.
6. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012;22:50-5.
7. Belinsky SA, Grimes MJ, Casas E, et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007;96:1278-83. (Pubitemid 46625083)
8. Shivapurkar N, Stastny V, Suzuki M, et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 2007;247:56-71. (Pubitemid 44959413)
9. Hubers AJ, Prinsen CFM, Sozzi G, et al. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer 2013;109:530-7.
10. Hubers AJ, Heideman DAM, Burgers SA, et al. World conference on lung cancer 2013. Abstract: validation of DNA hypermethylation analysis in sputum for the diagnosis of lung cancer. J Thorac Oncol 2013;8:S483.
11. Pauling L, Robinson AB, Teranishi R, et al. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci USA 1971;68:2374-6.
12. Röck F, Barsan N, Weimar U. Electronic nose: current status and future trends. Chem Rev 2008;108:705-25. (Pubitemid 351344454)
13. Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009;64:166-70.
14. Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005;171:1286-91. (Pubitemid 40740737)
15. D'Amico A, Pennazza G, Santonico M, et al. An investigation on electronic nose diagnosis of lung cancer. Lung Cancer 2010;68:170-6.
16. Peled N, Barash O, Tisch U, et al. Volatile fingerprints of cancer speci fic genetic mutations. Nanomedicine 2013;9:758-66.
17. Hubers AJ, Heideman DAM, Herder GJM, et al. Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. J Clin Pathol 2012;65:541-5.
18. Gold PM. The 2007 GOLD Guidelines: a comprehensive care framework. Respir Care 2009;54:1040-9.
19. Sobin LH, Gospodarowicz MK, WC. International Union Against Cancer (UICC) TNM classification of malignant Tumours. 7th edn. Wiley-Blackwell, 2009.
20. Steenbergen RD, Ongenaert M, Snellenberg S, et al. Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identi fies novel methylation events in cervical carcinogenesis. J Pathol 2013;231:53-62.
21. Dragonieri S, Schot R, Mertens BJA, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007;120:856-62. (Pubitemid 47542280)
22. Lewis NS. Comparisons between mammalian and artificial olfaction based on arrays of carbon black-polymer composite vapor detectors. Acc Chem Res 2004;37:663-72.
23. D'Amico A, Di Natale C, Falconi C, et al. Detection and identification of cancers by the electronic nose. Expert Opin Med Diagn 2012;6:175-85.
24. Hubers AJ, van der Drift MA, Prinsen CFM, et al. Methylation analysis in spontaneous sputum for lung cancer diagnosis. Lung Cancer 2014;84:127-33.
25. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7. (Pubitemid 34411720)
26. Cirincione R, Lintas C, Conte D, et al. Methylation pro file in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 2006;118:1248-53. (Pubitemid 43185613)
27. Van der Drift MA, Prinsen CFM, Hol BEA, et al. Can free DNA be detected in sputum of lung cancer patients? Lung Cancer 2008;61:385-90.
28. Leng S, Do K, Yingling CM, et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res 2012;18:3387-95.
29. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.
30. Mazzone PJ, Wang X-F, Xu Y, et al. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol 2012;7:137-42.
31. Di Natale C, Macagnano A, Martinelli E, et al. Lung cancer identi fication by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron 2003;18:1209-18. (Pubitemid 36776581)
32. Gordon SM, Wallace LA, Brinkman MC, et al. Volatile organic compounds as breath biomarkers for active and passive smoking. Env Heal Perspect 2002;110:689-98.
33. Van de Kant KDG, van der Sande LJTM, Jöbsis Q, et al. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Resp Res 2012;13:117.
34. Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009;180:1076-82.
35. Haick H, Broza YY, Mochalski P, et al. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev 2014;43:1423-49.